Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/INCANNEX-HEALTHCARE-INC-133985168/news/Incannex-Completes-Dosing-and-Therapy-in-Phase-2-PsiGAD-Clinical-Trial-Assessing-Psilocybin-as-45767022/?utm_source=whatsapp&utm_medium=social&utm_campaign=share